Legal compliance is a core requirement of Diamond Biofund’s operations and a critical foundation for gaining the trust of investors and other stakeholders. Diamond Biofund continuously monitors financial and investment-related policies and regulations issued by domestic and foreign regulatory agencies. Through effective management and evaluation mechanisms, the company strictly ensures that all operations comply with legal requirements.
The company continuously enhances employees’ awareness of legal compliance through education and promotion, ensuring they understand and adhere to legal regulations. Annual education and training courses on ethical management and legal compliance are conducted, focusing on corporate governance, risk management, and information protection. Courses are case-based to strengthen the understanding of legal compliance and ethical management concepts, management, and prevention of unethical behavior.
In 2024, neither Diamond Biofund nor its subsidiaries experienced any incidents of corruption or bribery, discrimination or harassment, customer privacy violations, conflicts of interest, money laundering, or insider trading.
Corporate Governance
The company strengthens the functions of the Board of Directors and functional committees, ensuring the Board fulfills its duty of care and supervises financial operations and internal control systems. The Corporate Governance Best Practices Guidelines and Rules for Performance Evaluation of Board of Directors are implemented, and governance practices are disclosed on the company’s website to enhance information transparency.
Personnel
Diamond Biofund fosters a corporate culture of legal compliance, building a trustworthy corporate reputation based on integrity. The company formulates relevant rules and internal control systems in accordance with legal requirements, constructing good corporate governance through practical operations. Employees are provided with governance, environmental protection, and labor rights training based on the nature of their work, ensuring that all employees comply with laws and internal regulations. New employees sign confidentiality agreements upon onboarding, including clauses to protect company trade secrets and cyber security, to prevent the leakage of commercial secrets that could harm the company. Contracts with trading partners are reviewed by the legal department to protect the company’s interests. Auditors verify employee compliance with business operations according to major cycles and important processes, effectively reducing the risk of legal violations. A stakeholder communication channel is established on the company website, allowing employees to report illegal activities promptly.
Diamond Biofund and its subsidiaries continuously implement internal control measures to ensure legal compliance. In 2024, there were no significant legal violations in corporate governance, environmental, labor, or human rights compliance, and internal audits did not find any major non-compliance issues.
| Corruption and bribery incidents | 0 cases |
| Discrimination and harassment incidents | 0 cases |
| Customer privacy breach incidents | 0 cases |
| Conflicts of interest incidents | 0 cases |
| Fraud, money laundering, insider trading incidents | 0 cases |
| Anti-competitive behavior, anti-trust and monopoly practices, market manipulation incidents |
0 cases |
| Other ethical management-related incidents or any significant legal violations |
0 cases |
醣基生醫股份有限公司
2017年9月27日登錄興櫃市場交易 (6586:TT)
公司所在地
台北，台灣
公司設立日期
2013
登錄公開市場
2017
公司官網
https://www.chopharma.com/cn/index.html
